Medical Uses and Adverse Effects of Psilocybin

References (35)

1. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355. PubMed CrossRef
2. Galvão-Coelho NL, Marx W, Gonzalez M, et al. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology Berl. 2021;238(2):341–354. PubMed
3. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78. PubMed CrossRef
4. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. PubMed CrossRef
5. Ross S, Agin-Liebes G, Lo S, et al. Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. ACS Pharmacol Transl Sci. 2021;4(2):553–562. PubMed CrossRef
6. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. PubMed CrossRef
7. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–1411. PubMed
8. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. PubMed
9. Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843–853. PubMed CrossRef
10. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234. PubMed
11. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627. PubMed CrossRef
12. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023; 327:120–127. PubMed CrossRef
13. Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983–992. PubMed CrossRef
14. Bogenschutz MP, Forcehimes AA, Pommy JA, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015; 29(3):289–299. PubMed CrossRef
15. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953–962. PubMed CrossRef
16. Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740. PubMed CrossRef
17. Ching THW, Grazioplene R, Bohner C, et al. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry. 2023;14:1178529. PubMed CrossRef
18. Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory investigation of a patient- informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383–1394. PubMed CrossRef
19. Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29:1947–1953. PubMed CrossRef
20. Koning E, Brietzke E. Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence. Trends Psychiatry Psychother. Published online May 1, 2023. doi: 10.47626/2237-6089-2022-0597. CrossRef
21. Krediet E, Bostoen T, Breeksema J, et al. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23(6):385–400. PubMed CrossRef
22. Więckiewicz G, Stokłosa I, Stokłosa M, et al. Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study. Front Psychiatry. 2023;14:1184023. PubMed
23. Reichelt A. Complexities of psychedelics for therapeutic use in obesity and eating disorders. J Psychiatry Neurosci. 2022;47(5):E366. PubMed CrossRef
24. Lowe H, Toyang N, Steele B, et al. Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders. Molecules. 2022; 27(8):2520. PubMed
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text revised. American Psychiatric Association; 2000.
26. Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48(10):1492–1499. PubMed CrossRef
27. McIntyre RS. Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. Expert Opin Drug Saf. 2023;22(10):881–883. PubMed CrossRef
28. Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 2022;111(4):886–895. PubMed CrossRef
29. Pokorny T, Preller KH, Kraehenmann R, et al. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016;26(4):756–766. PubMed CrossRef
30. Keeler MH. Chlorpromazine antagonism of psilocybin effect. Int J Neuropsychiatry. 1967;3(1):66–71. PubMed CrossRef
31. Quednow BB, Kometer M, Geyer MA, et al. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012;37(3):630–640. PubMed CrossRef
32. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–3902. PubMed CrossRef
33. Goel DB, Zilate S. Potential therapeutic effects of psilocybin: a systematic review. Cureus. 2022;14(10):e30214. PubMed CrossRef
34. MacCallum CA, Lo LA, Pistawka CA, et al. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217. PubMed CrossRef
35. Aaronson S, Miller T, Rudow S, et al. An open label study of synthetic psilocybin in bipolar type II depression. Biol Psychiatry. 2023;93(9):S132–S133.